Clinical Data

3D rendering of SARS-CoV-2 virus particles

Invivyd says Pemgarda sequel could be alternative to COVID shots

Invivyd has touted its follow-up to the FDA-authorized monoclonal antibody Pemgarda as potentially offering better protection than available vaccines.

James Waldron Jun 26, 2025 10:12am

Alto’s phase 2 depression trial misses primary efficacy endpoint

Jun 26, 2025 9:28am

Altimmune stock sinks on mixed ph. 2 MASH results for GLP-1 drug

Jun 26, 2025 8:41am

Biogen to take Spinraza follow-up into registrational studies

Jun 25, 2025 8:04am

Rivus weight loss drug shows MASH win, muscle-sparing potential

Jun 24, 2025 10:07am

MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b

Jun 24, 2025 10:06am